Citations

Clear

187 citation(s) found for "Ha, Gavin".

Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones
Viveiros, Anissa , Rasmuson, Jaslyn , Vu, Jennie , Yip, Cindy Ying Yin, Norris, Colleen M. , Norris, Colleen , Mulvagh, Sharon L. , Oudit, Gavin Y.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 4, 2020 | Volume: 320 | Issue: 1 | Pages: H296-H304

10.1152/ajpheart.00755.2020 | PMID 33275517 Get It

Biological sex is increasingly recognized as a critical determinant of health and disease, particularly relevant to the topical COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Epidemiological data and observational reports from both the original SARS epidemic and the most recent COVID-19 pandemic have a common feature: males are more likely to exhibit enhanced disease severity and mortality than females. Sex differences in cardiovascular disease and COVID-19 share mechanistic foundations, namely, the involvement of both the innate immune system and the canonical renin-angiotensin system (RAS). Immunological differences suggest that females mount a rapid and aggressive innate immune response, and the attenuated antiviral response in males may confer enhanced susceptibility to severe disease. Furthermore, the angiotensin-converting enzyme 2 (ACE2) is involved in disease pathogenesis in cardiovascular disease and COVID-19, either to serve as a protective mechanism by deactivating the RAS or as the receptor for viral entry, respectively. Loss of membrane ACE2 and a corresponding increase in plasma ACE2 are associated with worsened cardiovascular disease outcomes, a mechanism attributed to a disintegrin and metalloproteinase (ADAM17). SARS-CoV-2 infection also leads to ADAM17 activation, a positive feedback cycle that exacerbates ACE2 loss. Therefore, the relationship between cardiovascular disease and COVID-19 is critically dependent on the loss of membrane ACE2 by ADAM17-mediated proteolytic cleavage. This article explores potential mechanisms involved in COVID-19 that may contribute to sex-specific susceptibility focusing on the innate immune system and the RAS, namely, genetics and sex hormones. Finally, we highlight here the added challenges of gender in the COVID-19 pandemic.
Clearance of senescent cells during cardiac ischemia–reperfusion injury improves recovery
Dookun, Emily , Walaszczyk, Anna , Redgrave, Rachael E. , Palmowski, Paweł , Tual‐Chalot, Simon , Suwana, Averina Geffanie , Chapman, James , Jirkovský, Eduard , Sosa, Leticia Donastorg, Gill, Eleanor , Yausep, Oliver Emmanuel , Santin, Yohan , Mialet‐Perez, Jeanne , Grieve, David , Spyridopoulos, Ioakim , Arthur, Helen M. , Passos, João F. , Redgrave, Rachael , Suwana, Averina , Grieve, David , Spyridopoulos, Ioakim , Arthur, Helen M , Passos, João F , Richardson, Gavin D , Owens, W. Andrew , Taggart, Michael J. , Richardson, Gavin D.

Mayo Clinic

Aging Cell | September 30, 2020 | Volume: 19 | Issue: 10 | Pages: No page available

10.1111/acel.13249 | PMID 32996233 Get It

Abstract A key component of cardiac ischemia–reperfusion injury (IRI) is the increased generation of reactive oxygen species, leading to enhanced inflammation and tissue dysfunction in patients following intervention for myocardial infarction. In this study, we hypothesized that oxidative stress, due to ischemia–reperfusion, induces senescence which contributes to the pathophysiology of cardiac IRI. We demonstrate that IRI induces cellular senescence in both cardiomyocytes and interstitial cell populations and treatment with the senolytic drug navitoclax after ischemia–reperfusion improves left ventricular function, increases myocardial vascularization, and decreases scar size. SWATH‐MS‐based proteomics revealed that biological processes associated with fibrosis and inflammation that were increased following ischemia–reperfusion were attenuated upon senescent cell clearance. Furthermore, navitoclax treatment reduced the expression of pro‐inflammatory, profibrotic, and anti‐angiogenic cytokines, including interferon gamma‐induced protein‐10, TGF‐β3, interleukin‐11, interleukin‐16, and fractalkine. Our study provides proof‐of‐concept evidence that cellular senescence contributes to impaired heart function and adverse remodeling following cardiac ischemia–reperfusion. We also establish that post‐IRI the SASP plays a considerable role in the inflammatory response. Subsequently, senolytic treatment, at a clinically feasible time‐point, attenuates multiple components of this response and improves clinically important parameters. Thus, cellular senescence represents a potential novel therapeutic avenue to improve patient outcomes following cardiac ischemia–reperfusion.
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Pogue–Geile, Katherine L. , Serie, Daniel, Wang, Ying , Kim, Rim S., Tanaka, Noriko , Fumagalli, Debora , Taniyama, Yusuke , Li, Zhuo , Rastogi, Priya , Mamounas, Eleftherios P. , Lucas, Peter C. , Paik, Soonmyung , Thompson, E. Aubrey , Li, Zhuo , Serie, Daniel J, Lucas, Peter C , Song, Nan , Gavin, Patrick G. , Swain, Sandra M. , Mamounas, Eleftherios P. , Geyer, Charles E. , Wolmark, Norman

Mayo Clinic

JNCI Cancer Spectrum | August 27, 2020 | Volume: 4 | Issue: 5 | Pages: No page available

10.1093/jncics/pkaa058 | PMID 33241186 Get It

Abstract Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen receptor/progesterone receptor status, tumor size, and grade. Hazard ratios and 2-sided P values for recurrence-free survival of the predicted large- (n = 387), moderate- (n = 401), and no-benefit (n = 104) groups, based on the 8-gene signature were 0.47 (95% CI = 0.31 to 0.73, P < .001), 0.60 (95% CI = 0.39 to 0.92, P = .02), and 1.54 (95% CI = 0.59 to 4.02, P = .38), respectively (Pinteraction = .02), providing validation of the 8-gene signature in an independent study.
Diagnostic Accuracy of Limited MRI Protocols for Detecting Radiographically Occult Hip Fractures: A Systematic Review and Meta-Analysis
Wilson, Mitchell P. , Nobbee, Dorian, Dhillon, Suki, Katlariwala, Prayash , Low, Gavin , Murad, Mohammad H, Murad, M. Hassan , McInnes, Matthew D. F.

Mayo Clinic

American Journal of Roentgenology | July 13, 2020 | Volume: 215 | Issue: 3 | Pages: 559-567

10.2214/ajr.19.22676 | PMID 32755182 Get It

Diagnostic Performance of MRI in the Detection of Renal Lipid-Poor Angiomyolipomas: A Systematic Review and Meta-Analysis
Wilson, Mitchell P. , Patel, Deelan , Murad, M. Hassan , McInnes, Matthew D. F. , Katlariwala, Prayash , Low, Gavin , Murad, M Hassan , McInnes, Matthew D F

Mayo Clinic

Radiology | June 30, 2020 | Volume: 296 | Issue: 3 | Pages: 511-520

10.1148/radiol.2020192070 | PMID 32602827 Get It

Interpretation challenges of novel dual‐class missense and splice‐impacting variant in POLR3A‐related late‐onset hereditary spastic ataxia
Morales‐Rosado, Joel A. , Macke, Erica L. , Cousin, Margot A. , Oliver, Gavin R. , Dhamija, Radhika , Klee, Eric W. , Cousin, Margot A , Morales-Rosado, Joel A , Dhamija, Radhika

Mayo Clinic

Molecular Genetics & Genomic Medicine | June 29, 2020 | Volume: 8 | Issue: 9 | Pages: No page available

10.1002/mgg3.1341 | PMID 32597037 Get It

AbstractBackgroundRNA polymerase III (Pol III)‐related disorders are autosomal recessive neurodegenerative disorders caused by variants in POLR3A or POLR3B. Recently, a novel phenotype of adult‐onset spastic ataxia was identified in individuals with the c.1909+22G>A POLR3A variant in compound heterozygosity.MethodsWhole‐exome sequencing was performed in the proband and parents. Variants were confirmed by Sanger sequencing. RNA sequencing was performed to evaluate splicing implications.ResultsA 42‐year‐old female was evaluated for unexplained neurological findings with a slow progressive decline in gait and walking speed since adolescence. WES revealed a novel missense variant (c.3593A>C, p.Lys1198Arg) in exon 27 of POLR3A in compound heterozygosity with the c.1909+22G>A variant. Summary of previously reported clinical features from individuals with pathogenic biallelic alterations in POLR3A and adult‐onset phenotype is consistent with our findings. RNA analysis revealed c.3593A>G drives the production of four RNA transcript products each with different functional impacts.ConclusionThe novel dual‐class c.3593A>C variant in POLR3A causes an amino acid substitution and complex disruption of splicing. Our report supports the need to investigate variants near splice junctions for proper interpretation. Current interpretation guidelines need to address best practices for inclusion of predicted or measured transcriptional disruption pending functional activity or reliable transcript abundance estimates.
Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.
Rayes, Nadine , Peterson, Christine B. , Coffin, Tara B. , Gavin, Kathleen , Polinsky, Deborah , Crase, Jamie , Blank, Stephanie V. , Pradeep, Harsha M, Law, Sherman , Peterson, Christine , Swisher, Elizabeth M. , Bowen, Deborah J. , Norquist, Barbara M. , Bakkum‐Gamez, Jamie N. , Munsell, Mark F. , Nebgen, Denise R. , Olopade, Olufunmilayo I. , Zhou, Alicia Yiran , Levine, Douglas A. , D’Andrea, Alan D. , Lu, Karen H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1506-1506

10.1200/jco.2020.38.15_suppl.1506 Get It

1506 Background: Hereditary breast and ovarian cancer (HBOC) is preventable when genetic risk is identified. We aimed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing. Methods: MAGENTA (Making GENetic Testing Accessible) is a four-arm non-inferiority trial evaluating electronic genetic education and results delivery alone or combined with pre-test only, or post-test only telephone genetic counseling compared to mandatory pre- and post-test counseling (control arm) in women at risk of HBOC (NCT02993068). Regardless of assigned arm, all subjects with a pathogenic mutation received post-test telephone counseling. All subjects were enrolled electronically as part of either a family history cohort (FHC) or a cascade cohort (CC, known familial mutation). The primary outcome was cancer risk distress at 3 months and the trial was powered for the FHC. Secondary outcomes included completion of testing (i.e., received results), anxiety, depression, quality of life, and decisional regret, all measured by standardized scales. Results: Enrollment is complete and a total of 3,822 participants were randomized, 3,111 in FHC and 711 in CC. Participants were enrolled from all 50 states, but most were white/non-Hispanic (88%). Among participants that completed genetic testing, 173 (7.2%) had a mutation in a breast or ovarian cancer gene, with 114 (5.7%) of FHC and 59 (14.2%) of CC. In the primary intention-to-treat analysis of FHC, each of the three experimental arms was non-inferior to the control arm for distress at 3 months (p < 0.025/3 = 0.0083). In the CC, no and pre-test only counseling were also non-inferior (p < 0.025/3 = 0.0083). Distress was lowest in the arm with neither pre nor post-test counseling. Overall, 318 (18%) participants had very high distress at three month follow-up, and this rate was not significantly different across arms. Anxiety, depression and decisional regret did not have statistically significant differences across arms at follow-up. Test completion was highest in the no counseling arm (86.4%) and lowest in the control arm (60.6%). Conclusions: Electronic genetic education and results release without genetic counseling was non-inferior with regard to patient distress and was associated with higher test completion and lower distress. These results support use of a genetic testing paradigm providing individualized genetic counseling only for patients with positive test results. Clinical trial information: NCT02993068.
LeafCutterMD: an algorithm for outlier splicing detection in rare diseases
Jenkinson, Garrett , Li, Yang , Basu, Shubham , Cousin, Margot A. , Oliver, Gavin R. , Klee, Eric W.

Mayo Clinic

Bioinformatics | April 15, 2020 | Volume: 36 | Issue: 17 | Pages: 4609-4615

10.1093/bioinformatics/btaa259 | PMID 32315392 Get It

Abstract Motivation Next-generation sequencing is rapidly improving diagnostic rates in rare Mendelian diseases, but even with whole genome or whole exome sequencing, the majority of cases remain unsolved. Increasingly, RNA sequencing is being used to solve many cases that evade diagnosis through sequencing alone. Specifically, the detection of aberrant splicing in many rare disease patients suggests that identifying RNA splicing outliers is particularly useful for determining causal Mendelian disease genes. However, there is as yet a paucity of statistical methodologies to detect splicing outliers. Results We developed LeafCutterMD, a new statistical framework that significantly improves the previously published LeafCutter in the context of detecting outlier splicing events. Through simulations and analysis of real patient data, we demonstrate that LeafCutterMD has better power than the state-of-the-art methodology while controlling false-positive rates. When applied to a cohort of disease-affected probands from the Mayo Clinic Center for Individualized Medicine, LeafCutterMD recovered all aberrantly spliced genes that had previously been identified by manual curation efforts. Availability and implementation The source code for this method is available under the opensource Apache 2.0 license in the latest release of the LeafCutter software package available online at http://davidaknowles.github.io/leafcutter. Supplementary information Supplementary data are available at Bioinformatics online.
Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension: a systematic review and meta-analysis
Singh, Ranjit , Wilson, Mitchell P. , Katlariwala, Prayash , Low, Gavin , Murad, Mohammad H, Murad, M. Hassan , McInnes, Matthew D. F.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | April 13, 2020 | Volume: 32 | Issue: 2 | Pages: 237-245

10.1097/meg.0000000000001724 | PMID 32282542 Get It

Introduction The purpose of this systematic review and meta-analysis was to evaluate the diagnostic accuracy of liver and spleen stiffness on magnetic resonance elastography (MRE) for detecting clinically significant portal hypertension. Methods A systematic review of MEDLINE, EMBASE, Scopus, the Cochrane Library, and the Grey Literature through to 15 August 2019 was performed. Original articles with >10 patients evaluating liver and/or spleen stiffness on MRE using a reference standard of portal hypertension defined as intractable ascites, esophageal varices, encephalopathy and/or death were included in analysis. Patient, clinical, MRI, and diagnostic performance was independently acquired by two reviewers. Meta-analysis was performed using a bivariate mixed-effects regression model. Results Fourteen studies were included with 12 studies evaluating liver stiffness and eight studies evaluating spleen stiffness. The pooled and weighted sensitivity, specificity, and area under the curve (AUC) values for liver stiffness on MRE were 83% [95% confidence interval (CI) 72–90%], 80% (95% CI 70–88%), and 88% (95% CI 85–91%), respectively. The pooled and weighted sensitivity, specificity, and AUC values for spleen stiffness on MRE were 79% (95% CI 61–90%), 90% (95% CI 80–95%), and 92% (95% CI 89–94%), respectively. The liver and spleen stiffness sensitivity and specificity values were comparable when evaluating for esophageal varices only at of 80% (95% CI 66–89%) and 76% (95% CI 62–86%) for liver stiffness, and 75% (95% CI 52–90%) and 89% (95% CI 70–96%) for spleen stiffness. Discussion Liver and spleen stiffness on MRE can serve as a supplemental noninvasive assessment tools for detecting clinically significant portal hypertension. Spleen stiffness may be more specific and accurate than liver stiffness for detecting portal hypertension.